Evidence map›Paper›PMID 40496973›Full record

ArticleFrontiers in aging neuroscience2025

Protocol of a randomized, single-blind, controlled trial of an 18-month, home-based, high-intensity, exercise intervention in older, cognitively unimpaired

Stephen M Rao, Alexandria L Chorba, M J Helppi, Alina Tuladhar, Amanda L Penko, Sarah Holley, Brandon Nehls, Sabrina Paulino, Matthew C Streicher, Audrey Zhu and 15 more

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Stephen M RaoCenter for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Alexandria L Chorba *Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
M J Helppi *Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Alina TuladharCenter for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Amanda L PenkoDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
Sarah HolleyCenter for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Brandon NehlsCenter for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Sabrina PaulinoCenter for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Matthew C StreicherConcussion Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Audrey ZhuDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
Kellie BrueningDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
Sally DurgerianDepartment of Diagnostic Radiology, Imaging Institute, Cleveland Clinic, Cleveland, OH, United States.
Katherine KoenigDepartment of Diagnostic Radiology, Imaging Institute, Cleveland Clinic, Cleveland, OH, United States.
Mark LoweDepartment of Diagnostic Radiology, Imaging Institute, Cleveland Clinic, Cleveland, OH, United States.
Wanyong ShinDepartment of Diagnostic Radiology, Imaging Institute, Cleveland Clinic, Cleveland, OH, United States.
Stephen E JonesDepartment of Diagnostic Radiology, Imaging Institute, Cleveland Clinic, Cleveland, OH, United States.
Rachel GaliotoMellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Jagan A PillaiCenter for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Lynn M BekrisLerner Research Institute, Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.
James B LeverenzCenter for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.
Anson B RosenfeldtDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
Tamanna SinghDepartment of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, United States.
Gerald J BeckDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
J Carson SmithDepartment of Kinesiology, School of Public Health, University of Maryland, College Park, MD, United States.
Jay AlbertsDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.

Funding

University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Thomas J. Grabowski · 2020 to 2026
$29.0M
CYCLE-AD: Randomized Controlled Trial to Assess the Efficacy of Indoor Cycling in Slowing Disease Progression in Healthy Older Persons at Genetic Risk for Alzheimer's DiseaseR01AG070736 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI ALBERTS, JAY L., RAO, STEPHEN MARK · 2021 to 2025
$7.4M
NIA NIH HHS P30 AG066509NIA NIH HHS R01 AG070736
6 · The paper itself

Abstract

Background: The World Health Organization highlighted the potential protective role of exercise against cognitive decline, all-cause dementia, Alzheimer's disease (AD), and vascular dementia in healthy individuals. We have previously shown that exercise is particularly beneficial for older, cognitively unimpaired apolipoprotein E4 ( Design: CYCLE-AD is a randomized, single-blind, single-center, controlled trial of a home-based, high-intensity exercise intervention involving 150 older ε4 carriers (ages 65-80 years) who are healthy, cognitively unimpaired, and physically inactive. Participants are randomized into two groups: indoor cycling (IC) or usual and customary care (UCC) (target of 75 each). IC participants exercise 3×/week on an upright stationary cycle ergometer at a moderate-vigorous intensity for 18 months. Those in the UCC group are expected to maintain enrollment levels of activity. Outcomes: Comparison of IC and UCC groups on change in primary and secondary outcomes over baseline, 9-month, and 18-month evaluations. Primary outcomes are VO Hypotheses: Over an 18-month interval, physically inactive ε4 carriers who engage in high-intensity aerobic exercise will demonstrate less cognitive decline and hippocampal atrophy than physically inactive ε4 carriers who did not participate in a formal exercise program. Conclusion: Successful demonstration of a scalable, home-based, high-intensity aerobic exercise intervention in altering the trajectory of AD pathophysiology and its effects on cognitive functioning will transform AD treatment, improve patient outcomes and quality of life, and reduce healthcare costs.

Indexed as

Alzheimer’s diseaseAPOE ε4exerciseneuroprotectionrandomized clinical trial

Identifiers

PMID40496973
PMCPMC12149420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.